Ozempic Users Need Fewer Doses
New research shows many Ozempic users can maintain their weight loss with less frequent dosing. This finding could reshape how long-term GLP-1 therapy is approached for both diabetes and weight management — potentially reducing costs and injection burden for patients.
The recent study was conducted by physicians at Scripps Health and involved 30 patients who had already reached a weight plateau using GLP-1 medications. The research, published in the medical journal *Obesity*, followed participants who reduced their injection frequency for an average of 36 weeks. Of the participants, nine were on semaglutide (the active ingredient in Ozempic and Wegovy) and 21 were on tirzepatide (found in Mounjaro and Zepbound). Most patients moved to an injection every two weeks, though some extended the interval to as long as once every six weeks. The study found that most not only maintained their weight loss but also their improved blood pressure, cholesterol, and blood sugar levels. A significant driver for exploring dose reduction is the high cost of GLP-1 drugs, which can be hundreds of dollars for individual weekly doses and often aren't covered by insurance. The standard treatment protocol involves a gradual increase in dose, starting with a 0.25 mg weekly injection and potentially rising to a maximum of 2 mg, to manage side effects like nausea and diarrhea. The lead author of the Scripps study, Dr. Mitch Biermann, emphasized that their research investigated a structured "de-escalation" for maintenance, not the un-tested trend of "microdosing" seen on social media. He and other experts caution that the study was small, not randomized, and lacked a control group, meaning larger trials are necessary before clinical guidelines change. Experts in obesity medicine, like Dr. Fatima Cody Stanford, stress that obesity is a chronic disease. Previous large-scale studies, such as the STEP 4 trial, have shown that when patients stop taking semaglutide completely, they tend to regain a significant portion of the lost weight. This underscores the medical consensus that these medications are intended for long-term use. While the prospect of less frequent dosing is promising for reducing costs and patient burden, the current evidence still supports continuous treatment to maintain the health benefits achieved.
